1	Title 46
2	PROFESSIONAL AND OCCUPATIONAL STANDARDS
3	Part LIII: Pharmacists
4	Chapter 29. Prescription Monitoring Program
5	§2901. Definitions
6	A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context
7	clearly indicates otherwise.
8	* * *
9	Drugs of Concern—drugs other than controlled substances as defined by rule whose use requires tracking for
10	public health purposes or which demonstrate a potential for abuse, including any material, compound, mixture, or
11	preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts
12	of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the
13	specific chemical designation]:
14	a. butalbital when in combination with at least 325 milligrams of acetaminophen per dosage unit.
15	b. naloxone.
16	e. promethazine when present in oral liquid formulation.
17	d. c. gabapentin.
18	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.
19	HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007),
20	amended LR 36:755 (April 2010), effective September 1, 2010, LR 39:314 (February 2013), LR 40:1095, 1096 (June 2014), LR
21	41:684 (April 2015), amended by the Department of Health, Board of Pharmacy, LR 45:42 (January 2019), LR 47:84 (January
22	2021), repromulgated LR 47:248 (February 2021), amended LR
23	
24	* * *
25	
26	§2914. Record Retention of Prescription Transaction Monitoring Information
27	A. The board shall retain a minimum of five years of prescription transaction monitoring information for review by
28	persons authorized to access such information.
29	B. The board shall archive all prescription transaction monitoring information not available for direct or indirect
30	access-up to 10 years.
31	C. The board may respond to requests for archived prescription transaction information. remove and destroy
32	prescription monitoring information in excess of 10 years.
33	AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1006(G).
34	HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 47:85 (January 2021), repromulgated
35	LR 47:248 (February 2021), <u>amended LR</u>